Modern ChemotherapyVol.2 No.2(2013), Article ID:30489,17 pagesDOI:10.4236/mc.2013.22005
Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents
Australasian Institute of Medical Research, Brisbane, Australia; bill.cham@gmail.com
Copyright © 2013 Bill E. Cham. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received 24 February 2013; revised 26 March 2013; accepted 5 April 2013
Keywords: Cancer; Skin Cancer; Solamargine; Solasonine; BEC; Solasodine Rhamnosyl Glycosides; CuradermBEC5; Apoptosis; Antineoplastic; Targeted Therapy
ABSTRACT
In the last century, the discovery of cytotoxic agents was revolutionary for anticancer therapy. These therapies have resulted in better understanding of cancer in general. However, the development of agents that combine efficacy, safety and convenience remains a great challenge. The narrow, if not adverse, therapeutic index of most drugs, the damage not only to cancer cells, but also to normal and healthy tissue and the occurrence of resistance have limited anticancer efficacy. This review presents the development of promising novel cytotoxic solasodine rhamnosyl glycoside drugs that offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance and convenience in the treatment of patients with cancer.
1. INTRODUCTION
In the past 100 years our understanding of the biology of cancer has come a long way. We now have a reasonable working knowledge of how tumors initially form, grow and spread. Importantly, substantial information about features distinguishing tumor from normal cells is being accumulated, resulting in major new insights into cancer biology................
read all at
No comments:
Post a Comment